ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Nephrology

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,963Medicare Part D Prescriptions Filled, Including Refills

Rank: 1 out of 78

$669K Total Retail Price of All Prescriptions

Rank: 4 out of 78

487 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
30% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Connecticut
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 487 patients filled at least one prescription for a schedule two drug, compared to an average of 1%.

Schedule Three
Controlled Substances

9% of this provider’s 487 patients filled at least one prescription for a schedule three drug, compared to an average of 0%.

Risky Drugs to Seniors

1% of this provider’s 8,197 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 31%.

Prescription Price

$75 was the average price of a prescription from this provider, compared to $118 among peers.

Prescriptions per Patient

18 is the average number of prescriptions (including refills) per patient, compared to an average of 12.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Connecticut
ATORVASTATIN CALCIUM 423 388 1 7
SIMVASTATIN 405 383 2 9
METOPROLOL TARTRATE 326 289 3 10
AMLODIPINE BESYLATE 305 282 4 1
HYDROCODONE-ACETAMINOPHEN 294 226 S3 5 41
METOPROLOL SUCCINATE 269 253 6 16
FUROSEMIDE 246 231 7 2
LISINOPRIL 245 227 8 3
LEVOTHYROXINE SODIUM 223 215 9 15
ATENOLOL 170 157 10 22
ENALAPRIL MALEATE 155 142 11 42
METFORMIN HCL ER 154 132 12 51
PANTOPRAZOLE SODIUM 154 150 12 37
OMEPRAZOLE 149 128 14 18
ALLOPURINOL 133 129 15 8
LOSARTAN POTASSIUM 125 97 16 13
HYDROCHLOROTHIAZIDE 124 121 17 11
TRIAMTERENE-HCTZ 113 109 18 47
SERTRALINE HCL 112 112 19 61
ZOLPIDEM TARTRATE 104 78 20 26
LIPITOR 100 97 21 40
WARFARIN SODIUM 100 100 21 25
SYNTHROID 99 99 23 45
NEXIUM 95 90 24 38
DIOVAN 89 85 25 17
PREDNISONE 81 78 26 14
POTASSIUM CHLORIDE 79 79 27 66
FLUOXETINE HCL 72 70 28 69
QUINAPRIL HCL 72 68 28 69
TAMSULOSIN HCL 71 64 30 29
OXYCODONE-ACETAMINOPHEN 70 65 S2 31 71
PRAVASTATIN SODIUM 69 69 32 35
GLIMEPIRIDE 67 61 33 53
GEMFIBROZIL 65 65 34 74
ESCITALOPRAM OXALATE 64 64 35 56
CLOPIDOGREL 64 64 35 75
LEVOFLOXACIN 64 55 35 75
LOVASTATIN 59 59 38 80
AZITHROMYCIN 58 51 39 44
LOSARTAN-HYDROCHLOROTHIAZIDE 57 55 40 57
ADVAIR DISKUS 56 51 41 58
GABAPENTIN 54 47 42 27
PLAVIX 51 51 43 63
HYDRALAZINE HCL 51 46 43 20
GLYBURIDE 50 50 R 45 91
FINASTERIDE 50 43 45 91
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 12, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.